Interest in CLL motility and migration has recently increased following the recognition that the therapeutic effect of signal inhibitors including BTK inhibitors is accompanied by a compartment shift of cells between tissue and blood, suggesting that effects on cell interactions or migration may contribute to the therapeutic benefit of these agents [16]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.